WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017059223) COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2017/059223    International Application No.:    PCT/US2016/054729
Publication Date: 06.04.2017 International Filing Date: 30.09.2016
Chapter 2 Demand Filed:    31.07.2017    
IPC:
C12N 15/113 (2010.01)
Applicants: ARROWHEAD PHARMACEUTICALS, INC. [US/US]; 225 South Lake Avenue, Suite 1050 Pasadena, CA 91101 (US)
Inventors: MELQUIST, Stacey; (US).
KANNER, Steven; (US).
ROZEMA, David, B.; (US).
LEWIS, David, L.; (US).
ALMEIDA, Lauren, J.; (US).
WAKEFIELD, Darren, H; (US).
TRUBETSKOY, Vladimir, S.; (US).
PEI, Tao; (US).
LI, Zhen; (US).
ALMEIDA, Aaron; (US)
Agent: PURCELL, Angela, L.; (US)
Priority Data:
62/346,304 06.06.2016 US
62/383,221 02.09.2016 US
62/235,816 01.10.2015 US
Title (EN) COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA
(FR) COMPOSITIONS ET MÉTHODES PERMETTANT D'INHIBER L'EXPRESSION DU GÈNE DE LPA
Abstract: front page image
(EN)RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
(FR)La présente invention concerne des agents d'interférence ARN (ARNi) et des conjugués d'ARNi permettant d'inhiber l'expression du gène de LPA (apo(a)). L'invention concerne également des compositions pharmaceutiques comprenant un ou plusieurs agents d'ARNi de LPA avec éventuellement un ou plusieurs agents thérapeutiques supplémentaires. L'administration des agents d'ARNi de LPA selon l'invention dans des cellules hépatiques in vivo assure l'inhibition de l'expression du gène de LPA et le traitement de maladies cardiovasculaires et de maladies liées au système cardiovasculaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)